Nabili Mojtaba, Shokohi Tahereh, Janbabaie Ghasem, Hashemi-Soteh Mohammad Bagher, Ali-Moghaddam Kamran, Aghili Seyed Reza
Department of Parasitology and Mycology, Invasive Fungi Research Center, Sari, Iran ; Social Security Organization, Golestan, Iran.
J Glob Infect Dis. 2013 Apr;5(2):68-75. doi: 10.4103/0974-777X.112296.
The invasive aspergillosis (IA) is a serious opportunistic infection caused by various species of Aspergillus in immunocompromised individuals. Basically, rapid and early diagnosis prevents IA progression. In this study we performed a Real Time PCR/ Fluorescence Resonance Energy Transfer (FRET) for diagnosis of IA in hematologic malignancies and bone marrow transplant recipients.
Sixty two patients with hematologic malignancies and marrow transplant recipients were evaluated for IA in Sari and Tehran from 2009 to 2010. The primer and hybridization probe were designed to amplify the specific sequence of 18S rRNA genes using Light Cycler system and FRET. Galactomannan (GM) assay was performed on serums which obtained from selected patients using the Platelia Aspergillus kit.
According to the criteria defined by the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) for IA, 18 (29%) patients out of 62 patients were stratified into probable and possible groups. The female-to-male ratio was 1:2; the mean age of the patients was 36 years. The most common malignancies in these patients were acute lymphoblastic leukemia (38.9%). The minimum detection limit was 10 conidia (10(1) CFU/ml) equivalents (100 fg) per PCR reaction. GM assay was positive in 20.9% and real-time PCR probe set assay were positive in 17.7% patients who had clinical signs and host factor according to the mentioned criteria.
Using the Real-Time PCR/FRET assay in whole blood specimens seems to be a promising method for diagnosis of IA, especially when used in combination with the GM detection test.
侵袭性曲霉病(IA)是由多种曲霉菌引起的严重机会性感染,主要发生于免疫功能低下的个体。快速早期诊断可防止IA病情进展。本研究采用实时荧光定量聚合酶链反应/荧光共振能量转移(FRET)技术诊断血液系统恶性肿瘤和骨髓移植受者中的IA。
2009年至2010年期间,在萨里和德黑兰对62例血液系统恶性肿瘤患者和骨髓移植受者进行IA评估。使用Light Cycler系统和FRET技术设计引物和杂交探针,扩增18S rRNA基因的特定序列。采用Platelia Aspergillus试剂盒对选定患者的血清进行半乳甘露聚糖(GM)检测。
根据欧洲癌症研究与治疗组织和真菌病研究组(EORTC/MSG)制定的IA诊断标准,62例患者中有18例(29%)被分为可能和疑似组。男女比例为1:2;患者平均年龄为36岁。这些患者中最常见的恶性肿瘤是急性淋巴细胞白血病(38.9%)。每个PCR反应的最低检测限为10个分生孢子(10(1) CFU/ml)当量(100 fg)。根据上述标准,有临床症状和宿主因素的患者中,GM检测阳性率为20.9%,实时荧光定量PCR探针组检测阳性率为17.7%。
在全血标本中使用实时荧光定量PCR/FRET检测法似乎是一种有前景的IA诊断方法,尤其是与GM检测试验联合使用时。